Cognition Therapeutics (CGTX) Cash from Operations (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Cash from Operations of 5542000.0 for Q1 2026, up 43.89% year-over-year from 3851557.42 in Q1 2025, and down 61.25% quarter-over-quarter from 3437000.0 in Q4 2025.
Cognition Therapeutics (CGTX) Cash from Operations (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Cash from Operations for 7 consecutive years, with 5542000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 43.89% year-over-year to 5542000.0; the TTM figure through Mar 2026 stood at 20253000.0 (up 34.89% YoY), while the FY2025 annual figure was 24588000.0, up 13.65% from the prior year.
- Cash from Operations declined to 5542000.0 in Q1 2026 per CGTX's latest filing, from 3437000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 4000.0 in Q3 2022 and bottomed at 10184000.0 in Q4 2022.
- Historically, Cash from Operations has averaged 5479705.88 across 5 years, with a median of 5542000.0 in 2026.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 99.8% — and 2023, when it sank 103925.0%.
- Cognition Therapeutics' Cash from Operations stood at 10184000.0 in 2022, then surged by 46.43% to 5456000.0 in 2023, then tumbled by 53.63% to 8382000.0 in 2024, then jumped by 59.0% to 3437000.0 in 2025, then tumbled by 61.25% to 5542000.0 in 2026.
- Business Quant data shows CGTX's Cash from Operations at 5542000.0 in Q1 2026, 3437000.0 in Q4 2025, and 5651000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | -3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.05 Mn |
| Jun 30, 2026 | -3.05 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -5.62 Mn |
| Jun 30, 2025 | -5.62 Mn |
| Mar 31, 2025 | -9.88 Mn |
| Mar 31, 2025 | -9.88 Mn |
| Dec 31, 2024 | -8.38 Mn |
| Dec 31, 2024 | -8.38 Mn |
| Sep 30, 2024 | -6.85 Mn |
| Sep 30, 2024 | -6.85 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Mar 31, 2024 | -7.24 Mn |
| Mar 31, 2024 | -7.24 Mn |